Olema Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except for share amounts)
| Accumulated | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | |||||||||||||||||||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | |||||||||||||||||||||||
| Shares · Amount · Capital · (Loss) Gain · Deficit · Equity | |||||||||||||||||||||||
| Balances at December 31, 2022 | 40,287,097 | $ | 3 | $ | 408,333 | $ | (1,813) | (208,977) | $ | 197,546 | |||||||||||||
| Issuance of shares under equity private placement, net of issuance costs of $264 | 13,211,381 | 1 | 129,735 | — | — | 129,736 | |||||||||||||||||
| Stock-based compensation expense | — | — | 16,804 | — | — | 16,804 | |||||||||||||||||
| Exercise of stock options | 733,867 | — | 2,722 | — | — | 2,722 | |||||||||||||||||
| Issuance of shares under employee stock purchase plan | 333,503 | — | 1,050 | — | — | 1,050 | |||||||||||||||||
| Employee stock purchase plan expense | — | — | 452 | — | — | 452 | |||||||||||||||||
| Vesting of early exercised stock options | 18,640 | — | 80 | — | — | 80 | |||||||||||||||||
| Vesting of performance-based restricted stock unit awards | 217,000 | — | — | — | — | — | |||||||||||||||||
| Vesting of restricted stock awards | 191,296 | — | — | — | — | — | |||||||||||||||||
| Net unrealized gain on marketable securities | — | — | — | 2,160 | — | 2,160 | |||||||||||||||||
| Net loss | — | — | — | — | (96,655) | (96,655) | |||||||||||||||||
| Balances at December 31, 2023 | 54,992,784 | — | $ | 4 | — | $ | 559,176 | — | $ | 347 | — | — | (305,632) | — | $ | 253,895 | |||||||
| Issuance of shares and pre-funded warrants under equity private placement, net of issuance costs of $12,998 | 19,928,875 | 2 | 236,999 | — | — | 237,001 | |||||||||||||||||
| Issuance of shares under at-the-market offering, net of issuance costs of $166 | 1,772,278 | — | 22,787 | — | — | 22,787 | |||||||||||||||||
| Exchange of common stock shares for pre-funded warrants | (3,420,000) | — | — | — | — | — | |||||||||||||||||
| Stock-based compensation expense | — | — | 22,009 | — | — | 22,009 | |||||||||||||||||
| Exercise of stock options | 430,159 | — | 1,518 | — | — | 1,518 | |||||||||||||||||
| Issuance of shares under employee stock purchase plan | 112,853 | — | 859 | — | — | 859 | |||||||||||||||||
| Employee stock purchase plan expense | — | — | 573 | — | — | 573 | |||||||||||||||||
| Vesting of performance-based restricted stock unit awards | 403,000 | — | — | — | — | — | |||||||||||||||||
| Vesting of restricted stock awards | 92,659 | — | — | — | — | — | |||||||||||||||||
| Net unrealized loss on marketable securities | — | — | — | (204) | — | (204) | |||||||||||||||||
| Net loss | — | — | — | — | (129,474) | (129,474) | |||||||||||||||||
| Balances at December 31, 2024 | 74,312,608 | $ | 6 | $ | 843,921 | $ | 143 | (435,106) | $ | 408,964 | |||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.